While this upregulation of ER and ER‐related genes leads to a compensatory ‘escape’ pathway, it simultaneously creates an additional therapeutic target, with evidence that sustained anti‐HER2 therapy sensitizes tumor cells to endocrine therapies [7]. The gene discussed is ESR1; the disease is neoplasm.